corbus pharmaceuticals cbd

Corbus pharmaceuticals cbd

Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New York Academy of Sciences’ webinar on January 27, 2021 on the endocannabinoid system as a target for therapeutic agents.

The New York of Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science for the benefit of society. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online at

About Corbus

Corbus pharmaceuticals cbd

We are committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer.

Corbus’ pipeline encompasses two different approaches to immunology: small molecules that activate or inhibit the body’s endocannabinoid system and monoclonal antibodies that target integrins to inhibit activation of TGFβ.

Our CommitmentOur Commitment

We are a unique team of individuals who are high-achieving, innovative, creative, and above all else, passionate about what we do.

Our ScienceOur Science